HbA1c Response to Open-Label (OL) Empagliflozin (EMPA) with Metformin (MET) in Patients with Type 2 Diabetes (T2DM)

被引：0
|
作者：
Schernthaner, Guntram
Tinahones, Francisco J.
Goetz, Sophia
Lee, Christopher
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1288-P
引用
收藏
页码：A345 / A346
页数：2
相关论文
共 50 条
  • [1] HbA1c Response to Open-Label (OL) Linagliptin (LINA) with Metformin (MET) in Patients with Type 2 Diabetes (T2DM)
    Seufert, Jochen
    Softeland, Eirik
    Toorawa, Robert
    Lee, Christopher
    [J]. DIABETES, 2017, 66 : A345 - A345
  • [2] Efficacy and Safety of Empagliflozin (EMPA) in Younger, Overweight/Obese Patients with Type 2 Diabetes (T2DM) with HbA1c ≥8%
    Merker, Ludwig
    Lund, Soren S.
    Hantel, Stefan
    Salsali, Afshin
    Kim, Gabriel
    Broedl, Uli C.
    Woerle, Hans J.
    Hach, Thomas
    [J]. DIABETES, 2014, 63 : A280 - A281
  • [3] Empagliflozin (EMPA) Compared with Glimepiride (GLIM) as Add-on to Metformin (MET) for 2 Years in Patients with Type 2 Diabetes (T2DM)
    Ridderstrale, Martin
    Andersen, Knut Robert
    Zeller, Cordula
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2014, 63 : A70 - A70
  • [4] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans-Juergen
    Broedl, Uli C.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (03)
  • [5] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2014, 63 : A278 - A278
  • [6] Consistent Weight Changes Irrespective of Baseline HbA1c with the Combination of Empagliflozin/Linagliptin (EMPA/LINA) in Subjects with Type 2 Diabetes (T2DM)
    Barnett, Anthony H.
    Defronzo, Ralph A.
    Lewin, Andrew
    Patel, Sanjay
    Liu, Dacheng
    Kaste, Renee
    Broedl, Uli C.
    Lee, Christopher
    [J]. DIABETES, 2015, 64 : A656 - A656
  • [7] Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM)
    Kohler, S.
    Kaspers, S.
    Salsali, A.
    Zeller, C.
    Woerle, H. -J.
    [J]. DIABETOLOGIA, 2016, 59 : S26 - S26
  • [8] Modelling HbA1c Trajectory in Patients with Type 2 Diabetes Mellitus (T2DM)
    Mcewan, Phil
    Fellows, Jonathan
    Yapp, Rhiannon
    Bergenheim, Klas
    Qin, Lei
    Varol, Nebibe
    Bennett, Hayley
    Gordon, Jason
    [J]. DIABETES, 2016, 65 : A322 - A322
  • [9] Treatment Progression and Impact of HbA1C in Type 2 Diabetes (T2DM) Patients
    Dibello, Julia R.
    Levy, Brian
    Mehra, Maneesha
    [J]. DIABETES, 2010, 59 : A623 - A624
  • [10] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Pioglitazone with or without Metformin in Patients with Type 2 Diabetes (T2DM)
    Kovacs, Christopher Simon
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (03)
12345